Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Disparities in Immuno-oncology Outcomes in Detroit (DIODE)

Award Number: P20CA290450
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Disparities in Immuno-oncology Outcomes in Detroit (DIODE) - This application will address breast cancer in high-risk groups among residents of metropolitan Detroit, specifically evaluating differences in genetic regulation of tumor immune response in HER2+ breast cancer as an example of the type of transdisciplinary work that will be catalyzed through the robust grant-planning infrastructure developed in this P20. Many Detroit residents with HER2+ breast cancer belong to high-risk groups with substantially poorer outcomes overall, and among those treated with trastuzumab, even after controlling for clinical and patient-level factors, suggesting biologic factors may also contribute. Endogenous adaptive immunity may be a requirement for sustained tumor protection after monoclonal immune treatment, and the role of genetic regulation of immune tolerance, autoimmunity, and tumor immunity is well documented. Further, there is strong evidence for within-population differences in both immune pathway genetic variation and the tumor immune microenvironment. A better understanding of the mechanisms regulating response to HER2-targeted antibodies is critical for the development of improved clinical strategies, and the inclusion of a genetically heterogeneous patient population and consideration of group- and individual-level genetic differences is essential. The overarching goals of this P20 are (1) to identify ancestry-specific genetic regulators of macrophage function and response to HER2-targeted antibody therapy that potentially underlie differences in response to this targeted immunotherapy and (2) to establish a robust infrastructure to support and develop innovative, productive immuno-oncology and population science research collaborations. The application comprises one Research Project and an Administrative Core at an NCI-designated comprehensive Cancer Center in Detroit, Michigan. The aims of this P20 are (1) to accelerate translational research to reduce high mortality rates among patients with HER2+ breast cancer by characterizing ancestry-specific immune profiles with respect to the tumor environment and host genetic background to determine their contribution to response to treatment with anti-HER2 antibody therapies and (2) to strengthen the existing programmatic structure to facilitate interdisciplinary, translational research in immuno-oncology and population science, achieve R01/P01-level funding, and ultimately improve immuno-oncology outcomes among HER2+ breast cancer patients. This work will provide the basis for moving towards a more precision medicine approach to the use of immunotherapies to improve overall treatment response and identify novel biomarkers.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $413,265 )
2025	2025	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	9/19/2025	NON-COMPETING CONTINUATION	$413,265
														Subtotal = $413,265

Issue Date FY: 2024 ( Subtotal = $352,141 )
2024	2024	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	9/5/2024	NEW	$352,141
														Subtotal = $352,141

Grand Total All Awards = $765,406

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Disparities in Immuno-oncology Outcomes in Detroit (DIODE)

Award Number: P20CA290450

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer